Unique Phenotypic Features of IBD Linked to Primary Sclerosing Cholangitis
Overview
Primary sclerosing cholangitis (PSC) is strongly associated with inflammatory bowel disease (IBD), particularly ulcerative colitis (UC). PSC-associated IBD (PSC-IBD) exhibits distinct clinical and endoscopic features, including right-sided colitis predominance, rectal sparing, and backwash ileitis, differing from classical UC and impacting disease management and surveillance.
Background
PSC is a rare chronic cholestatic liver disease characterized by progressive bile duct inflammation and fibrosis, often leading to liver failure. It is closely linked with IBD, with 60–70% of PSC patients in Western countries having concomitant IBD, mostly UC. PSC-IBD differs from classical UC in clinical presentation, endoscopic findings, genetic background, and long-term outcomes, including a higher risk of colorectal neoplasia. These distinctions suggest PSC-IBD is a unique disease phenotype requiring tailored clinical approaches.
Data Highlights
Prevalence of PSC ranges from <1 to 32 per 100,000 population, highest in Northern Europe and North America. In Japan, PSC prevalence increased from 0.95 to 1.80 per 100,000 between 2007 and 2018. PSC affects 1.92–3.08% of UC patients and 0.69–1.28% of Crohn’s disease patients. In Western countries, 60–70% of PSC patients have IBD, while in Japan this is approximately 40%. The median time from PSC diagnosis to liver transplantation or death is 10–21 years.
Key Findings
PSC-IBD shows a distinct endoscopic phenotype with right-sided predominance of inflammation, differing from classical UC which typically starts in the rectum.
Rectal sparing and backwash ileitis are hallmark features of PSC-IBD, uncommon in conventional UC.
PSC-IBD patients have an increased risk of colorectal neoplasia compared to UC patients without PSC.
PSC-IBD differs genetically and in gut microbiome composition from classical UC, supporting its classification as a distinct disease phenotype.
Under-recognition of IBD in PSC patients, especially in Japan, may be due to mild or absent gastrointestinal symptoms, highlighting the need for routine ileocolonoscopy at PSC diagnosis.
Clinical Implications
Clinicians should recognize PSC-IBD as a distinct entity with unique phenotypic features that necessitate proactive diagnostic evaluation, including routine ileocolonoscopy regardless of symptoms. Surveillance strategies must account for the elevated colorectal cancer risk in PSC-IBD patients. Understanding the distinct pathogenesis of PSC-IBD may guide personalized management and improve long-term outcomes.
Conclusion
PSC-associated IBD represents a unique clinical and endoscopic phenotype distinct from classical UC, with important implications for diagnosis, surveillance, and management. Recognizing these differences is critical to addressing the unmet clinical needs in this patient population.
References
Nakamoto et al. 2024 -- Unique Phenotypic Features of Inflammatory Bowel Disease Linked to Primary Sclerosing Cholangitis
